Ravagalimab

• Target :

  TNF

• Related Pathways :

  Apoptosis

• Purity :

  0.995

• Bioactivity :

  Ravagalimab (ABBV-323) is a CD40 antagonist monoclonal antibody with an EC50 of 3.7 nM. Ravagalimab is being investigated for the treatment of inflammatory diseases such as Crohn’s disease and Sjögren’s syndrome (SS) . Research focuses on evaluating its pharmacological activity, efficacy, and safety in patients with primary Sjögren’s syndrome (pSS), highlighting its role in immune modulation.

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  2050816-56-1